Therapeutic HIV vaccine with Oxford technology achieves encouraging results

Published on November 4, 2022

A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.
Continue reading on website
Other news

Robots in fashion: how creatives are working with AI

November 4, 2022
Study on how creative people work collaboratively with artificial intelligence by Alentina Vardanyan, a PhD candidate at Cambridge Judge, wins award from Academy of Management.   Alentina VardanyanA paper by Alentina Vardanyan, a PhD candidate at Cambridge Judge Business School, on how creative people work collaboratively with artificial intelligence won the Best Dissertation-Based Paper Award fr

Careers with impact: how the Cambridge MBA puts ESG at the forefront

November 4, 2022
On the eve of COP27, with world leaders gathering in Egypt, we explore how an MBA from Cambridge Judge Business School can equip you for leadership in the sustainability or ESG space and we meet two MBA alumni whose career goals led them into the field after their Cambridge MBA.    “Leadership in organisations is all about leadership for global responsibility and leading change in society and bus